CCM

Concord Medical Services Holdings

Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2021, it operated a network of 16 cooperative centers based in 13 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

Concord Medical Services Holdings (CCM) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
B-
Factor Score 3.1 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -1.0
Rev Growth YoY 57.4%
Gross Margin 5.6%
Price Return 3M -6.1%
Price Return 12M -23.3%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.0
ROE -21.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) B- (3.1) D+ (1.7) C (2.4) C- (1.9) C (2.4)
2026-08-04 C+ (2.7) B- (3.1) D+ (1.7) C (2.4) C- (1.9) C (2.4)
2026-08-03 C+ (2.7) C+ (2.6) C- (2.1) C (2.4) C- (2.0) C (2.4)
2026-08-02 C+ (2.7) C+ (2.6) C- (2.1) C (2.4) C- (1.9) C (2.4)